OF PICTURES URES ES O PERFORMANCE PERFORMA ORMAN MANC
ON SMA RT ID EAS
WE WO RK H ARD
Enhancing scale and capabilities in line with global partnerships
Accelerating response to customer expectations
Developing IP-led niche molecules to sustain market leadership
Complying with stringent regulatory ecosystems across global markets
THE SE IN ITIAT ACC IVES ELER AND ATE ACH OUR IEVE VAL MEN UE C TS H REA ELP TION .
CON SIST ENT LY
WO RK F OR U S
SMA RT ID EAS
End-to-end solutions provider for multiple global partners
Strong products pipeline for future market scenarios
Consistently improving operating and financial performance
Extended global footprints
Talented multi-cultural workforce
THE BIG PICTURE
Strides Arcolab Limited (Strides) is one of India’s fastest growing developers, manufacturers and exporters of branded and generic finished pharmaceutical dosage form and specialty pharmaceuticals for regulated and emerging markets.
BUSINESS DIVISIONS
Pharmaceuticals Speciality (Agila)
VISION To be a profitable provider of high quality pharmaceutical products and solutions that create strategic value for our partners and to provide a rewarding workplace for our employees.
MISSION We innovate and operate in niche areas; deliver high-quality products and compelling service that ensure that our customers view us as a long term and reliable partner.
STRIDES IS A GLOBAL PHARMACEUTICAL COMPANY WITH OVER US$ 540 MILLION TURNOVER GLOBAL MARKETING REACH TOUCHES 75+ COUNTRIES ACROSS DEVELOPED AND EMERGING MARKETS 14 STATE-OF-THE-ART MANUFACTURING FACILITIES ACROSS SIX COUNTRIES OVER 2700 PEOPLE DRIVE OUR BUSINESS EXCELLENCE
CON TINU ED P ROG RESS
AC HRO NICL E
OF
Our progress is the result of our sustained efforts in developing niche, complex and innovative products across varied domains and formats.
Strides Pharma We are led by IP-driven licensing agreements and partnerships, emerging as a preferred end-to-end solution provider to global big pharma companies. Our facilities conform to the most exacting regulatory standards across global markets. Our business optimism is driven by the strength of our research & development initiatives and state-of-the-art manufacturing facilities.
LARGEST SOFT GEL MANUFACTURER IN INDIA AMONGST THE TOP 5 SOFT GEL MANUFACTURERS GLOBALLY
SUST AINE D VA LUE
A RE SEA RCH MOD EL F OR
R&D EDGE
A combination of sophisticated technical expertise, culture of innovation and deep market insight has resulted in a robust products pipeline to meet the growing requirements of Pharma majors.
Expertise in niche, highly variable and complex formulations Technical capabilities include Microparticle & Nanoparticle technology and Matrix technology Formulation capabilities include extended and modified releases, micro emulsions, taste and odour masking
A TEAM OF OVER 350 SCIENTISTS OFFER END-TOEND SOLUTIONS FROM CONCEPT TO DELIVERY
GLO BAL OPE RAT ION S
FAC ILITI ES F OR
DOMAIN FORMATS
REGULATORY APPROVALS
ORALS PLANT (BANGALORE, INDIA): ONE-STOP-SHOP FOR ALL ORAL DOSAGE FORMS CAPACITY 6 billion units annually (including 2.5 billion soft gels units) Soft gel capsules Hard gel capsules Liquid filled capsules Tablets (coated/uncoated) Powders and granules in sachets
US Food and Drug Administration (USFDA), USA Medicines and Healthcare products Regulatory Agency (MHRA), UK Therapeutic Goods Administration (TGA), Australia National Health Surveillance Agency (ANVISA), Portugal Medicines Control Council (MCC), South Africa World Health Organisation (WHO), USA
LIQUIDS AND SEMI-SOLIDS FACILITY (MILAN, ITALY): LOCATED STRATEGICALLY TO CATER TO THE US AND EU MARKETS CAPACITY Over 32 million topical units annually
DOMAIN FORMATS
Liquids: Syrups, solutions and suspensions Semi-solids: Creams, gels and ointments
REGULATORY APPROVALS
Italian Medicines Agency (AIFA) UNICEF and Clinton Foundation
PORTFOLIO COMPRISES 300+ PRODUCTS INCLUDING TABLETS, SOFT GEL CAPSULES, HARD GEL CAPSULES, SACHETS, LIQUIDS & SYRUPS AND CREAMS PIPELINE OF 20+ PRODUCTS TO BE COMMERCIALISED IN THE NEXT FIVE YEARS
Containment suites for highly potent drugs and Immunosuppressants
EXT E CAP N ABIL S I ITIES VE `
Exclusive manufacturing line for prescription Soft Gels
Hydrophilic and Hydrophobic technologies with clear and suspension fills and volatile ingredient encapsulation
Separate production blocks for anti-TB drugs and coloured products
360o fully automatic camera-based equipment for inspection of each tablet/capsule
Dedicated line for steroidal creams and products packaged in sachets for clinical trials
QUA AT T L I T HE C Y ORE
Our quality procedures are consistent with our vision and values and also take into consideration the contemporary global standards and trends. Consistent quality focus provides us a significant competitive advantage.
The quality management system is designed to achieve a robust product quality, and is part of the development process, technology transfer process, manufacturing & testing process and continuous monitoring and improvement programmes. We focus on information technology tools for effective knowledge management, which is well demonstrated through the implementation of an electronic Quality Management System (QMS), Laboratory Information Management System (LIMS), Learning Management System (LMS) and Chromatography Data Management System (CMS), among others.
THE QUALITY MANAGEMENT SYSTEM HAS INTERNALISED THE ICH EXPECTATION OF Q8 (PHARMACEUTICAL DEVELOPMENT), Q9 (QUALITY RISK MANAGEMENT) AND Q10 (PHARMACEUTICAL QUALITY SYSTEM)
ENH ANC AND ING TRU ST
PART NER ING WIT H CO NFID ENC E
Our valued partners rely on our expertise to help them enhance their existing product lines and bring products faster to the market.
We have established a reputation for efficient formulation development and technologies, manufacturing and operational flexibility and are looking forward to bringing these strengths to bear in our collaboration with partners.
PARTNERS TO MORE THAN 5 OF THE WORLD’S TOP PHARMACEUTICAL MAJORS IN AUSTRALIA, SOUTH AFRICA, EUROPE AND USA
RAT EGY THE RIGH T ST
PUT TING IN
PLAC E
We choose the right science, select the right market, partner with right people, marshal and manage diverse intellectual resources to compete in a challenging regulatory environment.
We proactively leverage operational synergies in areas like raw material, quality control and product placement, ensuring streamlined and on-time delivery. Our services include new product development, co-development and site transfers.
WE LOOK BACK WITH A SENSE OF PRIDE AT HOW MUCH WE HAVE ACHIEVED OVER THE LAST 20 YEARS, GROWING FROM A FLEDGLING ENTERPRISE TO ONE THAT IS RESPECTED GLOBALLY
THIS IS WHAT IT TAKES TO PERFORM IN ONE OF THE WORLD’S MOST COMPLEX HIGHLY REGULATED INDUSTRIES. AND DELIVER VALUE FOR STAKEHOLDERS, RESOLUTELY AND RESPONSIBLY..
com desa
rco. Registered Office 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 2789 3199
www .stri
Corporate Office Strides Arcolab Limited Strides House, Bilekahalli, Bannerghatta Road, Bangalore – 560076, India Tel: +91 80 6784 0000 / 6784 0738 Fax: +91 80 6784 0700 / 6784 0800